Clinical Trial

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

Study acronym: NEXPEDE-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-07-21; most recent amendment 2025-07-21.
Trial Details
NCT Number NCT05966493
Lead Sponsor Glaukos Corporation
Conditions Persistent Corneal Epithelial Defect
Enrollment 84 participants
Start Date 2023-08-17
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-24